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Does Vancomycin Resistance Affect Outcome in Patients With E. faecium Bacteremia? 
Garth S Herbert and Louise-Marie Dembry. Section of Infectious Diseases, Department 
of Internal Medicine, Yale University School of Medicine, New Haven, CT. 
The impact of vancomycin resistance on the outcome of patients with E. faecium 
bacteremia has not been definitively established, but it is an important factor in allocating 
hospital resources for controlling antibiotic-resistant organisms. This study is a 
retrospective analysis comparing the outcome of all patients who developed both 
vancomycin-sensitive (VS) and vancomycin-resistant (VR) E. faecium bacteremia at 
Yale-New Haven Hospital between 1992 and 2000. All patients with E. faecium 
bacteremia were evaluated with respect to risk factors for development of VR E. faecium 
bacteremia. Cases (patients with VR E. faecium bacteremia) were then matched to 
controls (patients with VS E. faecium bacteremia) on the basis of age, date and unit of 
hospitalization, severity of illness, and co-morbidities, including need for dialysis, 
immunosuppression, history of organ transplant, HIV status, same-hospitalization 
surgery, and presence of a prior oncologic diagnosis. The following factors were 
associated with increased risk of developing VR E. faecium bacteremia: exposure to 
third-generation cephalosporins (OR 3.69, Cl 1.72-7.89), vancomycin (OR 3.57, Cl 1.62- 
7.84), anti-anaerobic agents (OR 2.36, Cl 1.11-5.01), immunosuppressive agents (OR 
3.57, Cl 1.62-7.84), hospitalization in an ICU (OR 1.69, C! 0.82-3.51), history of organ 
transplant (OR 2.00, Cl 0.74-5.41), and need for dialysis (OR 1.67, Cl 0.70-3.97). 
Patients with VR E. faecium bacteremia were more likely to die than patients with E. 
faecium bacteremia prior to controlling for severity of illness (64.7% vs. 44.4%, OR 2.29, 
Cl 1.10 -4.79). After matching cases to controls on a 1:1 basis to control for severity of 
illness and other variables, the difference in mortality rates was no longer statistically 
significant (57.1% vs. 45.2%, OR 1.61, C! 0.68-3.82). 
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The problem of antibiotic resistance is a significant one for the practice of 
medicine, and hospitals often devote substantial resources to limiting the proliferation 
and spread of antibiotic resistant organisms. Excess costs incurred by hospitals as a 
result of infections caused by the six most common antibiotic-resistant nosocomial 
infections were estimated to be $1.3 billion/year{in 1992 dollars) by the Office of 
Technology Assessment of the US Congress (1). Further, this estimate included only 
those expenses encountered in the hospital, and did not encompass costs such as 
follow-up care, missed workdays and other related expenditures (1). Organisms such as 
methiciilin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant 
Pseudomonas aeruginosa are among the most concerning pathogens that require 
significant resources to control. In addition, enterococci have emerged as common 
nosocomial pathogens in recent years, becoming the second most common cause of 
nosocomial urinary tract infections and the third most common cause of nosocomial 
bacteremia (2). While possessing innate resistance to cephalosporins and many other 
antibiotics, the Enterococcus genus has only recently been elevated to the level of a 
more significant nosocomial pathogen when it developed resistance to vancomycin. 
Vancomycin-resistance enterococci (VRE) were first reported in Europe in 1986 
(3) . By 1988, isolates of VRE had appeared in the United States, and began 
disseminating quickly. Between January of 1989 and March of 1993, the percentage of 
VRE isolates reported to the National Nosocomial Infections Surveillance (NN1S) system 
increased by a factor of twenty, growing from 0.3% to 7.9% of all enterococcal isolates 
(4) . Even more striking, by 1998, more than 20% of all ICU enterococcal isolates 
reported to the NNIS were resistant to vancomycin (5). The rapid increase in prevalence 
of a multiply resistant organism for which there are few therapeutic options demanded 
attention, but it was unclear whether enterococci had actually become more virulent. 
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At Yale-New Haven Hospital, recognition of the first strain of vancomycin- 
resistant enterococci occurred in 1992. The number of vancomycin-resistant 
enterococcal isolates (the vast majority of which were strains of E. faecium) increased 
over the next two years. The spread of resistant organisms prompted the institution of 
screening (through rectal or peri-rectal cultures) and subsequent isolation of patients 
who were positive for VRE. Beginning in 1994, this screening was directed towards 
patients in the medical intensive care unit and those on patient care units with a high 
percentage of dialysis and HIV patients, as these units were found to have the highest 
prevalence of VRE based on surveillance. In 1998, the population screened for VRE 
was expanded to include the oncology unit, based on an increase in VRE colonization 
noted via periodic prevalence culture surveys. In spite of these interventions, the 
number of patients with VRE bacteremia continued to rise through the end of the 
decade. 
The experience at YNHH with VRE was very similar to those at hospitals 
elsewhere in the country. One of the concerns over this organism’s rapid spread was 
the loss of vancomycin as an effective pharmacologic agent for enterococcal infections. 
However, clinicians remained (and remain, to this day) divided on the significance of 
vancomycin-resistant enterococci, particularly when part of polymicrobial infections. 
Enterococci are not considered nearly as pathogenic as S. aureus or P. aeruginosa. 
However, there has been concern that VRE could pass vancomycin resistance onto an 
organism such as MRSA, thereby eliminating the primary therapeutic option for a 
formidable pathogen. While S. aureus with reduced susceptibility to vancomycin were 
documented in the U.S. in 1997, it was not through the same mechanism as employed 
by enterococci (6). Nonetheless, concerns over the Enterococcus species itself - which 
includes organisms that are typically found in the normal flora of our intestine - persist. 
But, whether we are justified in devoting significant hospital resources to combat the 
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spread of an organism that is prevalent, but of unknown pathogenicity, is a question that 
remains unanswered. 
Background 
As gram-positive cocci, enterococci were originally classified as Group D 
streptococci, and were differentiated from other Streptococcus species by their ability to 
grow on 6.5% NaCI. As a whole, enterococci are remarkably hardy, capable of growing 
in medium with a pH of 9.6 or containing 40% bile, as well as at temperatures as low as 
10°C and as high as 45°C (7). In the 1980s, when it was determined that enterococci 
differed from streptococci not only in their ability to grow under harsher conditions but 
also genetically, they were reclassified under their own genus (2). 
Clinical enterococcal isolates are most commonly determined to be either 
Enterococcus faecalis, which comprises roughly 80 - 90% of isolates, or Enterococcus 
faecium, comprising an additional 5 - 15% (2). Laboratories differentiate between the 
two species based on their differing abilities to ferment sugars. E. faecium is able to 
ferment arabinose, while E. faecalis is unable to do so. In addition to the most common 
species, approximately 5% of isolates belong to the other species of Enterococcus, 
which include E. gallinarum, E. casseliflavus, E. durans, E. avium, and E. raffinosis (2). 
These different species of enterococci demonstrate varying mechanisms of antibiotic 
resistance. As discussions of the relevance of enterococci are based in no small part on 
the organism’s resistance, this subject merits further explanation. 
Resistance in enterococci 
Just as enterococci have been known to be a causative agent of endocarditis for 
decades, certain aspects of its inherent resistance to antibiotics have been known for 
decades as well. It was observed in the 1940s that treating endocarditis caused by 
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Enterococcus species with penicillin resulted in worse outcomes than streptococcal 
endocarditis treated with the same regimen (8). Further investigations since that time 
have shown enterococci to be resistant to cephalosporins, anti-staphylococcal 
penicillins, aminoglycosides at low-levels, and frequently to fluoroquinolones. It has 
been postulated that the emergence of enterococci as nosocomial pathogens is related 
to the increasingly frequent use of cephalosporins over the same time period and 
consequent selection for enterococci (2). 
The mechanisms of antibiotic resistance employed by Enterococcus species are 
varied. With regard to penicillin resistance, E. faecalis is known to employ p-lactamases 
while E. faecium produces different penicillin-binding proteins (8). Concerning the latter 
mechanism, one common penicillin-binding protein (PBP) expressed by E. faecium, PBP 
5, demonstrates much lower affinity for penicillin than do other enterococcal PBPs. 
Predictably, the loss of the ability to produce PBP 5 by E. faecium has been shown to 
dramatically increase penicillin susceptibility in that species (2). 
Enterococci also demonstrate varying mechanisms of resistance to 
aminoglycosides. In fact, even resistance to gentamicin and streptomycin are mediated 
by different mechanisms. Resistance to one is not a certain indication that the organism 
will be resistant to the other (2). Resistance to gentamicin, kanamycin, tobramycin, and 
amikacin occur through the actions of an acetyltransferase enzyme that inactivates 
these aminoglycosides (2). Another enzyme, streptomycin adenyltransferase, mediates 
resistance to streptomycin. In addition, moderate-level resistance to all types of 
aminoglycosides can occur as a result of low cell-wall permeability (which can be 
overcome by concomitant administration of penicillins) (2). 
As is the case in its resistance to other antibiotics, enterococcal resistance to 
vancomycin can occur in a variety of ways. The five phenotypic types of vancomycin 
resistance in enterococci have been designated VanA, VanB, VanC, VanD, and VanE. 
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The first two types, VanA and VanB, result from the presence of genes that enterococci 
do not possess by nature (2). The first gene, VanA, mediates inducible resistance to 
both vancomycin and teicoplanin, another glycopeptide antibiotic (2). Such resistance 
can be induced not only by exposure to glycopeptides, but also by antibiotics such as 
bacitracin and polymyxin B (2). This gene allows enterococci to produce cell wall 
precursors that terminate in D-Ala-D-Lac, instead of the D-Ala-D-Ala sequence that is 
bound and inhibited by vancomycin (2). Essential to the resistance mediated by VanA 
are two other genes that allow for key steps in mediation of resistance. VanH produces 
an enzyme that catalyzes production of D-Lac, which is incorporated into cell-wall 
precursors. In addition, VanX produces a peptidase that hydrolyzes D-Ala-D-Ala cell 
wall precursors, but has no activity in degrading D-Ala-D-Lac (2). Further, two other 
genes, designated VanR and VanS, control expression of the Van H and Van X genes. 
The protein-products of these genes increase expression of the VanHAX cluster in the 
presence of antibiotics such as vancomycin (2). Of note, this entire gene complex 
resides on a transposon in enterococci, thus permitting transmission of the resistance 
genes to other bacteria. 
The VanB gene mediates resistance to vancomycin, but enterococci expressing 
this gene are still susceptible to teicoplanin. The protein produced by this gene also 
mediates the production of D-Ala-D-Lac, once again replacing the target of vancomycin 
by providing different cell-wall precursors (2). This mechanism of resistance also 
requires homologues of VanH, VanX, VanR, and VanS. This system is induced by 
vancomycin but not by teicoplanin (2). 
Both the VanA and VanB genes can be found on mobile genetic material that can 
be transferred from one Enterococcus to another (2). It is precisely this potential for 
mobility that allows resistance to be transferred to other enterococci, or possibly to other 
similar microbes such as S. aureus. Such transmission has been demonstrated in the 
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laboratory, where E. faecalis passed on genes coding for vancomycin resistance to S. 
aureus. This transfer was demonstrated both in vitro, on filter paper, and also in vivo, 
after strains of the two bacteria were mixed and incubated on the skin of mice (9). 
Fortunately, the VanB gene is usually located on the main enterococcal chromosome, 
and in this case is not readily transferable. Most likely as a consequence of its ability to 
be transmitted from one bacterium to another, VanA is the mode of resistance most 
frequently found in the United States (2). 
Other variants of vancomycin resistance are far less common. VanC typically 
mediates low levels of vancomycin-resistance, and is found in enterococcal species less 
frequently observed in the hospital setting (E. gallinarum, E. casseliflavus, E. flavescens) 
(2). VanD is a rare mode of resistance observed in E. faecium, and works by a 
mechanism similar to VanA and VanB. However, it is found on the main chromosome, 
and thus is not transferable (2). Finally, VanE has been documented in E. faecalis, and 
resembles resistance mediated by the VanC gene (2). 
Related research 
Numerous studies have investigated the epidemiology of vancomycin-resistant 
enterococci. A complete understanding of the patterns of resistance just described can 
allow one to predict some of the findings. For example, since the most common form of 
vancomycin resistance is mediated by VanA, the expression of which is increased in the 
presence of vancomycin, one can correctly surmise that administration of vancomycin 
selects for carriage of VRE. This expectation has been confirmed in several studies (10, 
11, 12, 13, 14,15, 16). Furthermore, given that enterococci are inherently resistant to 
cephalosporins, administration of cephalosporins (particularly those of the third 
generation) is associated with emergence of VRE (10, 11, 12, 14). 

7 
Most studies concerning VRE have shown that greater length of hospitalization 
prior to the development of bacteremia, ICU care, and increasing severity of illness are 
all risk factors for infection with VRE (12, 14, 17, 18, 19, 20). One study correlated use 
of central venous catheters with VRE bacteremia (19). Another found a history of AIDS / 
HIV and liver transplant to be highly associated with VRE bacteremia as compared to 
VSE bacteremia (11). An association between dialysis and vancomycin-resistant E. 
faecium infection or colonization was established in one study (20), while other studies 
made a more specific association between hemodialysis and VRE bloodstream 
infections (16, 21). 
While previous studies cite common factors for the development of VRE 
infections, they have not been conclusive in determining whether vancomycin-resistance 
independently affects outcome of patients with enterococcal bacteremia. One reason for 
this persistent uncertainty is the heterogeneity of published investigations. Studies have 
been difficult to compare because investigators have looked at very different patient 
populations; some have focused only on ICU patients, others on transplant patients, and 
others on the entire hospital population. A focus on different Enterococcus species - E. 
faecalis and E. faecium vs. E. faecium alone - also limits direct comparison, as 
bacteremia with E. faecium has been associated with worse outcome than bacteremia 
with E. faecalis (12, 22). In addition, the use of different control populations (a study by 
Edmond used patients without bacteremia (23), while most others used patients with 
VSE bacteremia), and varying attempts to correct for the effect of severity of illness on 
outcome inhibits direct comparison of available studies. 
Among the studies using various populations, enterococcal species, and 
matching techniques, some failed to show higher mortality among patients with VRE as 
opposed to VSE bacteremia. Mainous et al examined enterococcal bacteremia (both E. 
faecium and E. faecalis) in patients in the surgical intensive care unit. The study found 
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no difference in mortality between 10 patients with VRE bacteremia and 31 patients with 
VSE bacteremia; also, the mortality rate for VRE bacteremia was similar to the mortality 
rate for bacteremia due to other organisms (41% vs. 41.7%) (14). Another study 
compared 93 patients with VRE bacteremia to 101 patients with VSE bacteremia, the 
latter selected because of positive culture dates close to the patients with VRE 
bacteremia. The authors found the APACHE II score to be most closely associated with 
death; vancomycin-resistance did not have a statistically significant effect on outcome 
(19). A third study compared 72 patients with VRE bacteremia to 188 patients with VSE 
bacteremia (neither group was limited with regard to enterococcal species). The authors 
concluded that vancomycin resistance was more of a marker for severe illness rather 
than a predictor of mortality (16). 
Among the studies which did find that vancomycin-resistance contributed to 
mortality, one was a comparison of 53 cases with VRE bacteremia matched to 53 
controls with VSE bacteremia on the basis of severity of illness, age, and hospital unit. 
The study included both E. faecium and E. faecalis bacteremia, and found vancomycin- 
resistance to be an independent predictor of mortality (17). In a study performed across 
twenty-two institutions, 150 patients with VRE bacteremia were compared to 150 
patients with VSE bacteremia. The study examined both E. faecium and E. faecalis, and 
demographic data were similar in the two groups. APACHE II scores were used in 
multivariate analysis of the data, but comparative APACHE II scores of the two groups 
were not reported. Results from this comparison indicated that vancomycin-resistance 
was associated with higher mortality, as patients with VRE bacteremia were nearly twice 
as likely to die than those with VSE bacteremia (52% vs. 27%, p < 0.05) (11). Finally, 
another study matched 27 patients with VRE bacteremia to 27 patients without 
bacteremia based on age, underlying illness, and other factors. The study determined 
that the bacteremic patients were twice as likely to die as those without bacteremia; 

however, they noted that the mortality rate for their group with VRE bacteremia was 
comparable to the rate of those with VSE bacteremia in other studies (23). 
9 
Among the studies that exclusively examined E. faecium, the primary cause of 
VRE infections, results are similarly mixed as to whether vancomycin-resistance is a 
predictor of worse outcome. Garbutt et al. performed a retrospective study of all patients 
with E. faecium bacteremia at Barnes-Jewish Hospital in St. Louis over a 28-month 
period. The main cohort of patients consisted of 23 patients with VSE and 46 patients 
with VRE who all had clinically significant bacteremia (defined as two positive blood 
cultures, or one positive blood culture with another site, other than stool, positive for E. 
faecium). Severity of illness was evaluated using APACHE II scores, the Organ System 
Failure Index, the Chow index (referred to as the Korvick Index in this study - a severity 
of illness score established and validated by previous studies of bacteremic patients), 
and the Systemic Inflammatory Response Syndrome classification scheme. The authors 
concluded that while each of their severity of illness scores was positively associated 
with risk of death, vancomycin-resistance was not independently associated with 
mortality. However, the authors postulated that a larger sample size might lead to a 
different conclusion (24). 
Stosor et al. completed a retrospective investigation of patients with E. faecium 
bacteremia at Northwestern Memorial Hospital between 1992 and 1995. Medical 
records of fifty-three patients were reviewed, of which 32 patients had VSE bacteremia, 
and 21 had VRE bacteremia. The authors used the fore-mentioned Chow Index to 
control for severity of illness. On statistical analysis, the two groups had similar severity 
of illness scores, but the mortality rate differed significantly (76% mortality for patients 
with VRE bacteremia, vs. 41% for patients with VSE bacteremia, p = 0.009) (15). This 
difference in mortality was attributed to vancomycin-resistance given the otherwise 
similar characteristics of the two groups. One shortcoming of this study was the 
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inclusion of nine patients with bacteremia that did not meet the author’s own definition of 
clinical significance (requiring a minimum of two positive cultures, or one positive culture 
with a documented source of infection). As no deaths were attributed to VRE 
bacteremia if the bacteremia did not meet the definition of clinical significance (15), this 
may have biased the outcome of the study. Moreover, as six of these patients were in 
the VSE group and the numbers in each group were very small to start with, the 
significance of the outcome of this study is questionable. 
A third study examined consecutive patients on a liver transplant service who 
developed E. faecium bacteremia. The authors compared 54 patients with VRE 
bacteremia to 48 patients with VSE bacteremia, and concluded that vancomycin- 
resistance was an independent predictor of mortality (18). However, the study did not 
attempt to control for severity of illness. While all patients were on a liver-transplant 
service, examination of the patients’ co-morbidities showed differences between the 
numbers of transplant patients in each group (and thus patients who were actively 
immunosuppressed), the number of patients who developed bacteremia in the ICU 
(patients who were probably more severely ill), and the number of patients who were on 
hemodialysis or mechanical ventilation. When these differences are considered, the 




As mentioned above, while many studies have examined the effect of 
vancomycin-resistance on outcome of patients with bacteremia, there is no general 
consensus on whether vancomycin-resistance is an independent predictor of mortality 
for these patients. This question demands a carefully structured investigation capable of 
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providing a credible answer. Since the majority of vancomycin-resistant enterococci are 
E. faecium, we chose to investigate the outcome of bacteremia specifically caused by 
this species. Furthermore, as severity of illness undoubtedly has an effect on mortality, 
we paid particular attention to this variable. We also tried to avoid a shortcoming of 
previous smaller investigations by including a larger number of VRE cases and controls, 
electing to investigate a ten-year period at Yale-New Haven Hospital. Determining 
whether vancomycin-resistance plays a significant role in the outcome of enterococcal 
bacteremia may permit the hospital to appropriately allocate limited resources in 
controlling the spread of antibiotic-resistant pathogens. 
The hypothesis to be tested is as follows: Vancomycin-resistance does not have 
an independent effect on mortality of patients with E. faecium bacteremia after 
controlling for severity of illness. 
Patients and Methods 
The study is a retrospective, case-control analysis of patients with Enterococcus 
faecium bacteremia at Yale-New Haven Hospital, a 944-bed university-affiliated, tertiary 
care, teaching hospital. Dr. Dembry obtained a list of all patients with enterococcal 
bacteremia between July 1992 and October 2002 from the Clinical Microbiology 
Laboratory. All patients greater than 2 years of age who had clinically significant 
bacteremia were included. Clinically significant bacteremia was defined as positive 
blood cultures from two different sites, or one set of positive cultures with another site of 
enterococcal infection (urinary tract infection, wound infection, etc.). Rectal swabs and 
sputum samples positive for VRE were not considered as sites of infection, and were not 
included based on our definition. Bacteremia was classified as either vancomycin- 
sensitive enterococci (VSE) or vancomycin-resistant enterococci (VRE), with the 
threshold for defining an organism as resistant to vancomycin set at an MIC > 32 pg/mL. 
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In addition, for patients with multiple episodes of bacteremia, only the first instance was 
considered in our study. 
After examining medical records to determine whether patients met inclusion 
criteria (patient age and clinically significant bacteremia), I reviewed the records for the 
following: gender and ethnicity; antibiotics received and the duration of treatment, both 
before and after the documented bacteremia; co-morbidities, including history of cancer, 
HIV, transplant, renal failure requiring dialysis, and same-admission surgery; exposure 
to immunosuppressive agents prior to the development of bacteremia; severity of illness 
using the Korvick Scale, based on the patient’s condition on the day blood cultures were 
drawn; and survival outcome (discharge or death) for that hospitalization. 
The Korvick Scale has been validated in prior studies as an effective measure of 
severity of illness in patients with bacteremia (25, 26). Point assignments for the criteria 
considered by the Korvick Scale are listed in Table 1. Points assigned in each category 
are totaled to create the overall severity of illness score, with the possible total score 
ranging from 0 to 14 points. 
Table 1. Korvick Scale 
Mental Status Mechanical Ventilation 
Normal 0 N/A 0 
Disoriented 1 Required 2 
Stupor 2 
Coma 4 
Patient Temperature Cardiac Arrest 
< 99.8°F 0 N/A 0 
> 99.8°F and < 104°F 1 Present 4 
> 104°F 2 
Blood Pressure 
Unchanged from baseline 0 
Systolic drop > 20mm Hg, 
diastolic drop > 10mm Hg, 
or requiring pressors 2 
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While the Korvick Scale measures the patient's severity of illness on the day of 
diagnosis of bacteremia, it does not reflect each patient's co-morbid illnesses. However, 
since this was a retrospective study and many subjects were hospitalized outside of the 
ICU, the thorough documentation that would have made it possible to use other severity 
of illness scores (such as the APACHE II scale) was not available. 
Culture isolates were determined to belong to Enterococcus species by the 
Clinical Microbiology Laboratory based on their ability to grow on 6.5% NaCI and on bile- 
esculin agar. Isolates were further characterized as E. faecium based on their ability to 
ferment arabinose. In addition, antimicrobial sensitivity was assessed by disk diffusion 
method according to NCCLS guidelines. 
Patients were considered to be immunosuppressed if they were actively 
receiving chemotherapeutic agents, were on a post-transplant immunosuppressive 
regimen, or received an equivalent of at least 20mg per day of prednisone for a 
minimum duration of five days, prior to the episode of bacteremia. Also, mortality was 
evaluated only in the context of the same hospitalization as the bacteremia. Patients 
who were discharged to inpatient hospice (including 4 patients who had VRE 
bacteremia, and 2 patients who had VSE bacteremia) were considered to have died 
during their hospitalization. 
I performed the statistical analysis using EpiCalc 2000, version 1.02. Statistical 
significance was assessed using the chi-squared test or Fisher’s exact test for 
dichotomous variables and with the Student’s t test for ordinal variables. P values < 0.05 
were considered to be statistically significant. 
In total, 85 patients were found to have clinically significant vancomycin-resistant 
(VR) E. faecium bacteremia between August 1992 and December 2000, and 45 patients 
were found to have clinically significant vancomycin-sensitive (VS) E. faecium 
bacteremia between August 1992 and October 2002. The time period for identification 
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of VS E. faecium bacteremia cases was extended in order to find an adequate number 
of controls. (Of note, the treatment of bacteremia with VS E. faecium was unchanged, 
so this measure would be unlikely to bias results in any way). Cases were defined as 
patients who had clinically significant VR E. faecium bacteremia, and controls were 
patients with clinically significant VS E. faecium bacteremia during the aforementioned 
periods. 
Cases were matched with controls on the basis of severity of illness, age, nursing 
unit, date of positive culture, and co-morbidities including need for dialysis, immuno¬ 
suppression, history of organ transplant, HIV status, same-hospitalization surgery, and 
prior oncologic diagnoses. The matching system was similar to techniques used in prior 
studies of bacteremia and fungemia (17, 27, 28), and was weighted with the most 
important match characteristics being similar severity of illness (SOI) scores, dates of 
hospitalization (to ensure comparable treatment), and patient ages. Other 
characteristics on which the matching was based included nursing unit and co-morbid 
illnesses. Points were allocated to each potential case-control combination in the 
following manner: 2 points for an SOI score within 1, and 2 more points for the same 
SOI; 2 points for the same gender; 2 for an age within 10 years, with an additional 2 
points if the age was within 5 years; 2 points if the patients were hospitalized on the 
same nursing unit; 2 points if the date of positive culture was within 2 years, with an 
additional point if it was within 12 months; and 2 points for each of the following co¬ 
morbidities in common: end stage renal disease, HIV status, history of transplant, 
surgery during the index hospitalization, a prior oncologic diagnosis, or immuno¬ 
suppression. Matching of cases to controls (on a 1:1 ratio) was based on the highest 
score of at least 14 points. Cases that did not have a score of at least 14 for any case- 
control combination were excluded from the study group, as they were not similar 
enough to any controls. 
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Of note, while the goal at the outset of the study was to focus on E. faecium 
bacteremia to avoid confounding by inter-species differences, we were unsure if there 
would be enough controls with VS E. faecium bacteremia. Consequently, we identified 
several patients with VS E. faecalis bacteremia that were hospitalized at similar times on 
similar nursing units to patients with VR E. faecium bacteremia to serve as potential 
controls. Collection of data on these forty patients gave us valuable, firsthand insight 




160 patients with VR E. faecium bacteremia were identified in the report from the 
Clinical Microbiology Laboratory. Of these patients, 2 were autopsy specimens, 4 charts 
were unavailable, 1 patient was a newborn, and 68 did not have clinically significant 
bacteremia, leaving 85 patients for analysis. Of 111 patients with VS E. faecium 
bacteremia, 3 were autopsy specimens, 3 charts were unavailable, 4 later had VRE 
bacteremia during the same hospitalization (and were thus considered to be cases), 10 
were newborns, and 46 did not have clinically significant bacteremia, leaving 45 patients 
for analysis. 
The 85 patients with VR E. faecium bacteremia and 45 patients with VS E. 
faecium bacteremia were analyzed in two separate groups. The main group included all 
cases and controls, who by definition had E. faecium bacteremia. The study group 
included 42 cases matched on a 1:1 basis with 42 controls. 43 case patients were 
unable to be matched with controls due to the relative paucity of patients with 
vancomycin-sensitive E. faecium bacteremia, and 3 controls with VSE bacteremia were 
not similar enough to any case patients to be matched. In addition, charts for 40 
patients with VSE bacteremia secondary to E. faecalis were reviewed (for reasons 
described earlier). Statistics from this population are only included in a direct 
comparison with the 45 patients with VS E. faecium bacteremia. 
VSE Bacteremia - both E. faecium and E. faecalis 
Since there were not a large number of patients with VS E. faecium bacteremia, 
we considered combining patients with either VS E. faecium or E. faecalis bacteremia as 
controls. However, evaluation of the data from 45 patients with VS E. faecium 
bacteremia compared to 40 patients with VS E. faecalis bacteremia demonstrated that 
this would not be an appropriate comparison. Patients with vancomycin-sensitive 
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bacteremia fared far differently based on whether they were infected with E. faecium or 
E. faecalis. Although the patients with VSE bacteremia, regardless of species, were 
similar in demographic and other characteristics (Table 2), VS E. faecium bacteremia 
resulted in higher mortality than VS E. faecalis (OR 3.77, 95% Cl 1.38 - 10.31). 
Table 2. Demographics Among Patients with VSE 
E. faecium E. faecalis 
Bacteremia Bacteremia 
Number of patients 45 40 
Mean age (range) 51.4 (4-89) 60.7 (4-90) 
Median age 52 68 
Gender (% male) 62.5% 47.5% 
Race 
White 66.7% 72.5% 
African-American 24.4% 20.0% 
Hispanic 6.67% 7.5% 
Other 2.2% 0% 
Unknown 0 % 0% 





P value OR (95% Cl) 
0.038 
0.707 
3.77 (1.38- 10.31) 
Of note, while the Korvick Scores for severity of illness were similar, the average 
ages of the two populations (those with different species of VSE) were statistically 
different. Each group included two patients under the age of 20, but both the mean and 
median age was higher for patients with VS E. faecalis. Also, the mean hospitalization 
time prior to bacteremia for the two groups was similar (15.9 ± 19.8 days for E. faecium 
vs. 13.5 ± 17.9 days for E. faecalis), suggesting that the number of nosocomial infections 
was comparable between the two groups. 
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Main Group - All VR and \/S E. faecium 
VR E. faecium bacteremia first appeared at Yale-New Haven Hospital in 1992, 
and the percentage of E. faecium isolates resistant to vancomycin increased over the 
next several years (Fig 1). During the study period, the number of patients with clinically 
significant VRE bacteremia, as defined in this study, peaked in 1997. 
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Figure 1. The bars depict the number of patients with clinically significant E. 
faecium bacteremia (blood cultures drawn from at least two sites, or one positive 
blood culture with another site of infection) that occurred each year at Yale-New 
Haven Hospital, 1992 - 2000. Patients are divided into those with VRE 
bacteremia and those with VSE bacteremia. The line reflects the percentage of 
all E. faecium bacteremias that were vancomycin-resistant during each year. 
Mortality rates for both VRE and VSE bacteremia did not follow any clear trend 
over the study period (Figure 2). This is not surprising for the VSE population, as 
vancomycin was available for treatment of such infections during the entire study period. 
Pharmacotherapeutic options for VRE bacteremia changed towards the end of the study 
period, with the introduction of quinupristin-dalfopristin in September of 1999, and the 
approval of linezolid in April of 2000. However, these options were used for only four 
study patients, with mixed results. One patient treated with quinupristin-dalfopristin 
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survived, while another died of underlying disease after recovering from bacteremia. 
One of two patients treated with linezolid survived. Of note, the patient who died after 
treatment with linezolid had a severity of illness (Korvick) score of 4, while the other 
patient had a score of 2. 
Chloramphenicol was the most frequent antibiotic prescribed for patients with 
VRE bacteremia over the course of the study, but outcome for these patients was not 
significantly different than those treated with other medications (including gentamicin and 
doxycyline, as well as linezolid and quinupristin-dalfopristin). The mortality rate for 
patients treated with chloramphenicol was 63.9%, while patients treated with other 
regimens had a mortality rate of 54.5% (p = 0.304). 
Fig 2. Mortality Rate 
Figure 2 shows the mortality rate over time for both VRE and VSE bacteremia at 
Yale-New Haven Hospital. Statistics were calculated based on all clinically 
significant cases of bacteremia. 
More than three quarters of the study population had a Korvick Score less than 
or equal to 3 (Figure 3). There were relatively few patients at the higher end of the 
Korvick scale, particularly in the group with VSE bacteremia. The highest Korvick Score 
in each group was 7 points (out of a possible 14 points). 
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Fig. 3. Severity of Illness 
Figure 3 shows the number of patients observed for each Korvick Score, with 
separate totals for those with VRE vs. VSE bacteremia. 
The Korvick Scale proved to be an accurate predictor of outcome in this study of 
patients with E. faecium bacteremia, particularly those with VRE. The group of patients 
with VR E. faecium bacteremia shows a relatively clear trend towards higher mortality 
given a higher Korvick Score (Fig. 4). The apparent dip in mortality at a score of 2 may 
be a consequence of the fact that only seven patients had a score of 2, providing less 
than half the number of observations for a score of 1 (29 patients) or 3 (16 patients). 
Also, more than 80% of patients with VR E. faecium bacteremia and a Korvick Score of 
at least 5 died; one patient with a score of 6 was the only survivor at this end of the 
Korvick Scale. 
The trend towards higher mortality with increasing Korvick Score is less definite 
in patients with VSE bacteremia. The relatively few patients with both VSE bacteremia 
and high Korvick Scores may have precluded us from noting a clearer trend towards 
higher mortality in this population. 
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Fig 4. Mortality by Severity of Illness 
Korvick Score 
Figure 4 shows the mortality rate at each severity of illness score. Mortality rates 
were calculated for patients with clinically significant VRE or VSE bacteremia. 
Among the main group, the demographic data was similar between patients with 
VRE bacteremia and those with VSE bacteremia (Table 3). The VRE group was slightly 
older than the VSE group, but this difference was not statistically significant. In addition, 
the VSE group had a slightly higher percentage of males (64.4% as opposed to 56.5%), 
but again, this difference was not statistically significant. Prior to controlling for severity 
of illness, patients with VRE bacteremia had a higher crude mortality rate, 64.7% vs. 
44.4%. In this analysis, VRE bacteremia was associated with mortality by an odds ratio 
of 2.29 (95% Cl 1.10 - 4.79). These two groups also had differing severity of illness 
scores, with the average Korvick score being 2.46 in the VRE group, and 2.11 in the 
VSE group; however, this difference was not statistically significant (p = 0.314). 
The two groups had similar proportions of patients with polymicrobial bacteremia, 
32.9% in the VRE group compared to 40.0% in the VSE group. On the other hand, the 
percentage of patients in each group with persistent bacteremia (at least one blood 
culture drawn on a different day was positive) was much higher in the VRE group - 
60.0% of patients had persistent VRE bacteremia, while 35.6% of patients had persistent 
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VSE bacteremia. The association between VRE and persistent bacteremia was 
statistically significant (OR 2.72, 95% Cl 1.29 - 5.75). 
Table 3. Characteristics of Patients with E. faecium Bacteremia 
Number of patients 
Age 


























P value OR (95% C!) 
0.250 
0.72 (0.34 - 1.51) 
0.314 
0.76 (0.36- 1.62) 
2.72 (1.29-5.75) 
2.29 (1.10-4.79) 
As previously mentioned, all patients were considered to have clinically 
significant bacteremia in the presence of two positive blood cultures from different sites, 
or one positive blood culture with another documented site of infection. Of the patients 
with only a single positive blood culture, the additional site of infection varied (Table 4). 
Additionally, 28 patients with one positive blood culture for VRE were not considered to 
have clinically significant bacteremia although they were documented as being colonized 
with VRE by positive rectal swabs. The total number of clinically significant cases of 
bacteremia was significantly higher in the VRE group than the VSE group (53.1% vs. 
40.5%, p = 0.0414). 
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Table 4. Concurrent Sites with VRE 
VRE VSE P value 
Patients with > 1 positive blood 
160 111 
culture during study period 
Patients with 2 or more positive blood cultures 65 28 0.0086 
Patients with only 1 positive blood 
culture, and a positive culture from; 
Urine 8 8 
Wound 3 2 
Ascites 3 0 
Pleural fluid 2 0 
CSF 0 1 
Bile 3 0 
Catheter tip 1 5 
Autopsy 0 1 
Sputum 3 0 
Stool / Rectal swab * 28 0** 
Total considered significant 85 (53%) 45 (41%) 0.0414 
*These sites were not considered significant sites for purposes of the case definition in patients 
with only one blood culture positive for VRE or VSE. 
**Rectal swab cultures were reported as either positive or negative for VRE; the Clinical 
Microbiology Laboratory did not report the presence of VSE in stool, rectal, or peri-rectal cultures. 
Next, several risk factors analyzed in previous studies of enterococcal 
bacteremia were reviewed in our patient population. Many of the same trends were 
found in our patient population (Table 5). Patients with VRE were more likely to have 
been exposed to a minimum of three days of either 3rd generation cephalosporins (OR 
4.13, 95% Cl 1.91 - 8.93) or vancomycin (OR 3.57, 95% Cl 1.62 - 7.84) prior to 
developing bacteremia. The association between vancomycin and VRE is even more 
pronounced when considering all patients who had one or more doses of vancomycin 
(OR 5.91,95% Cl 2.67 - 13.09). Also, patients exposed to anti-anaerobic agents (a 
minimum of three days of clindamycin or metronidazole) were at a higher risk of 
becoming infected with VRE (OR 2.36, 95% Cl 1.11 - 5.01). Finally, exposure to 
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fluoroquinolones was associated with a significantly increased risk of infection with VRE; 
48.2% of the VRE group received fluoroquinolones prior to developing bacteremia vs. 
20.0% of the VSE group (OR 3.73, 95% Cl 1.60 - 8.68). 
Table 5. Antibiotic Exposures 
Number of patients 







OR (95% Cl) 
Cephalosporins (CP) 72.9% 42.2% 3.69 (1.72 -7.89) 
3rd Gen. CP 67.1% 35.6% 4.13 (1.91 -8.93) 
Vancomycin 56.5% 26.7% 3.57 (1.62-7.84) 
Clindamycin or metronidazole 54.1% 33.3% 2.36 (1.11 - 5.01) 
Penicillin class 36.5 % 35.6% 1.04 (0.49-2.21) 
Aminoglycosides 30.6% 17.8% 2.04 (0.83-4.98) 
Fluoroquinolones 48.2% 20.0% 3.73 (1.60-8.68) 
Other antibiotics 49.4% 31.1% 2.16 (1.01 -4.63) 
Further analysis of the data yielded additional risk factors for VRE bacteremia 
(Table 6). Patients with VRE bacteremia were significantly more likely to have been in 
the hospital longer prior to the onset of bacteremia (27.2 days vs. 15.9 days, p = 
0.0193). With regard to the total number of days of hospitalization, there was a slight 
difference between the two groups, 52.6 days in the VRE group vs. 41.4 days in the VSE 
group, however this difference was not statistically significant (p = 0.121). The number 
of hospital days after the first positive blood culture for enterococci was identical for the 
two groups, 24.6 days for patients with either VSE or VRE bacteremia. However, the 
apparent equality in the length of stay after diagnosis of bacteremia is a result of the 
number of patients with VRE bacteremia who died shortly after documentation of 
positive blood cultures; for survivors, the average number of days in the hospital post 

bacteremia was 31.1 days for the VRE group and 23.0 days for the VSE group. This 
difference was not statistically significant (p = 0.245). 
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In addition, patients on immunosuppressive therapy were found to be at a 
statistically significant increased risk for VRE bacteremia (OR 3.57, 95% Cl 1.62 - 7.84). 
Hospitalization in one of the intensive care units was associated with VRE bacteremia, 
but was not statistically significant (OR 1.69, 95% Cl 0.82 - 3.51). Also, dialysis was 
associated with an increased risk of VRE bacteremia, with 29.4% of patients requiring 
dialysis prior to the onset of VRE bacteremia vs. 20.0% prior to VSE bacteremia. This 
increased risk associated with dialysis was also not statistically significant. Additionally, 
there was a non-significant trend for patients with a history of organ transplant to 
develop VRE bacteremia (OR 2.00, 95% Cl 0.74 - 5.41). In this study, other co¬ 
morbidities including HIV status, surgery during the same hospitalization, and an 
oncologic diagnosis were not found to be associated with risk for VRE bacteremia. 
Table 6. Risk Factors for VRE Bacteremia 
VRE VSE P value / 
Bacteremia Bacteremia OR (95% Cl) 
Number of patients 85 45 
Avg days of hospitalization 
before bacteremia 
27.2 15.9 0.0193 
Total hospital days 52.6 41.4 0.121 
ICU stays 55.3% 42.2% 1.69 (0.82 -3.51) 
Dialysis 29.4% 20.0% 1.67 (0.70-3.97) 
HIV positive 12.9% 13.3% 0.97 (0.33 -2.81) 
Transplant 23.5% 13.3% 2.00 (0.74-5.41) 
Surgery (this 
hospitalization) 
38.8% 42.2% 0.87 (0.42 - 1.81) 
Oncologic Diagnosis 35.3% 31.1% 1.21 (0.56-2.61) 
Immunosuppression 56.5% 26.7% 3.57 (1.62 -7.84) 
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Study Group - Matched Cases and Controls 
For the patients with VRE bacteremia who were successfully matched to controls 
with VSE bacteremia, the two populations had similar characteristics (Table 7). 
Furthermore, after matching on the basis of severity of illness, patient age, date of 
hospitalization, and co-morbidities, the mortality rates in the two groups differed 
somewhat, but not significantly (57.1% vs. 45.2%, OR 1.61, 95% Cl 0.68 - 3.82). The 
average severity of illness score differed slightly between the two groups, but not 
significantly. With regard to other factors examined (including ICU status and co¬ 
morbidities), the two groups did not differ significantly in any category. 





P value OR (95% Cl) 
Number of patients 42 42 
Age 50.3 53.7 0.376 
Gender (% male) 28 (66.7%) 27 (64.3%) 
Race 
White 29 (69.1%) 28 (66.7%) 
African-American 11 (26.2%) 10 (23.8%) 
Flispanic 1 (2.38%) 3 (7.14%) 
Other 1 (2.38%) 1 (2.38%) 
ICU stay 20 (47.6%) 16 (38.1%) 1.48 (0.62-3.52) 
Dialysis 9(21.4%) 9 (21.4%) 1.00 (0.35-2.84) 
HIV positive 8 (19.1%) 6 (14.3%) 1.41 (0.44-4.49) 
Transplant 11 (26.2%) 5 (11.9%) 2.63 (0.82 -8.38) 
Surgery (this 
hospitalization) 
19 (45.2%) 17 (40.5%) 1.21 (0.51 -2.89) 
Oncologic Diagnosis 14 (33.3%) 13 (31.0%) 1.12 (0.45-2.79) 
Severity of Illness 
Score (Korvick) 
1.81 2.00 0.595 




This study supports the results of Garbutt et al. who observed that vancomycin- 
resistance does not have a significant effect on outcome of enterococcal bacteremia 
after controlling for severity of illness. A long-standing question has been whether 
infection with vancomycin-resistant enterococci is merely a marker of severe illness or 
actually portends a worse prognosis. Our study suggests the former. The relatively low 
pathogenicity of enterococci has never been debated. In fact, prior to the development 
of vancomycin resistance, it was debated as to whether enterococcal bacteremia even 
merited treatment (29, 30). While it was ultimately determined that patients receiving 
appropriate treatment had slightly improved outcomes, this debate underscores the lack 
of virulence of enterococci. 
The development of vancomycin-resistance renewed the debate over 
enterococci again; does VRE lead to higher mortality than VSE? There is currently no 
evidence that VRE possesses virulence factors lacking in VSE to suggest differences in 
pathogenicity. Furthermore, several studies are concordant in demonstrating that 
patients who are more severely ill are more likely to develop infection with VRE (13, 16, 
20, 21, 23). Likewise, the present study suggests that patients who develop VRE 
bacteremia are more likely to die than those developing VSE bacteremia, but only before 
controlling for severity of illness. 
it might be postulated that mortality is increased among those with VRE 
bacteremia because of a lack of treatment options. This did not appear to be the case in 
our study. There were no pan-resistant VRE isolates encountered during review of 
susceptibilities, and most of the isolates were sensitive to chloramphenicol. While 
patients treated with chloramphenicol did not have better outcomes than patients treated 
with other regimens, the higher mortality rate for those patients may represent treatment 
bias, as the risks of chloramphenicol may have limited its use to the most severely ill 
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patients. Future studies are not likely to document lack of treatment options as a source 
of poorer outcome either, as linezolid and quinupristin-dalfopristin now provide additional 
options in the treatment of VRE. 
Another interesting finding of our study was that E. faecium was associated with 
significantly higher mortality rates than E. faecalis among those patients with 
vancomycin-sensitive enterococcal bacteremia. This was in spite of the fact that the 
average age of the patients with VS E. faecalis was significantly higher than the patients 
with VS E. faecium bacteremia. A difference in virulence between the two species had 
been suggested previously. In one study, patients with VS E. faecalis bacteremia were 
compared to patients with E. faecium bacteremia, with the latter group containing some 
patients infected with VRE (12). The current study population highlights this inequality 
between different Enterococcus species, and suggests caution in interpreting results of 
earlier studies. Many of these studies grouped both species in the VSE category, while 
the VRE group was primarily composed of E. faecium. At Yale-New Haven Hospital, 
94.1% of the patients with a blood culture positive for VRE during the study period were 
infected with E. faecium, while only 13.1% of the patients with VSE over the same time 
period were infected with this enterococcal species. Thus, VRE and VSE categories 
largely encompass different species of enterococci. Interpretation of virulence based on 
resistance to vancomycin requires cognizance of this fact. 
A mechanism accounting for the observed difference in virulence between E. 
faecium and E. faecalis has not been described. Both E. faecium and E. faecalis 
possess cytolysins (which also act as hemolysins) and aggregation substances (which 
facilitate transmission of DNA, including transposons that carry genes mediating 
resistance). E. faecalis alone produces virulence factors such as proteases and 
hyaluronidase (31). Conversely, there is documentation of an uncharacterized 
substance produced only by E. faecium that inhibits phagocytosis in vitro (32). While 
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this suggests a possible mechanism for the observed difference in virulence between the 
two species, it is clear that the pathophysiology of enterococcal infections is not 
completely understood. In any event, such inter-species differences would also suggest 
that E. faecium and E. faecalis must be considered separate entities in investigations of 
enterococci, as previously suggested by Mackowiak (7). 
If the premise is correct that vancomycin-resistance does not affect mortality or 
other clinical outcomes, the possibility that VRE is associated with increased cost of care 
could be reason alone to pursue aggressive (but cost-efficient) methods of containment. 
We did not determine the hospital costs for each patient, but the number of days spent in 
the hospital (a major determinant of total costs for hospitalization) was not significantly 
different between the VRE and VSE groups. More importantly, while the number of 
hospital days prior to bacteremia was significantly longer for the VRE group, the number 
of hospital days after documentation of bacteremia was very similar. Studies that 
document excess costs for VRE patients (as opposed to their counterparts with VSE) 
may be inappropriately attributing increased costs to VRE when it is more likely that the 
costs are related to patient’s severity of illness. Stosor et al., for example, reported that 
patients with VRE bacteremia were hospitalized significantly longer before developing 
bacteremia as compared to those with VSE bacteremia (34.8 days vs. 16.7 days) (15). 
However, they attributed all differences in the cost of the hospitalizations to VRE, when 
in fact a significant amount of these excess costs were most likely incurred before the 
bacteremia. 
Of course, factors other than the number of days of hospitalization can affect 
costs of treatment. Newer antibiotics used to combat VRE infections will certainly affect 
the balance of costs; both linezolid and quinupristin-dalfopristin are far more expensive 
than either vancomycin or chloramphenicol. Furthermore, these drugs may be 
necessary to treat many infections with VRE that do not involve bacteremia. At Yale- 
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New Haven Hospital, bacteremia alone accounts for only 25 - 30% of all VRE infections, 
so the number of other infections that may require these expensive drugs is significant. 
Clearly, the issue of whether vancomycin-resistance leads to excess costs when treating 
enterococcal infections requires further study. 
Aside from the possibility that vancomycin-resistance may increase the cost of 
treating enterococcal infections, another important reason to continue efforts in 
preventing the spread of VRE would be to prevent the spread of resistance to other 
organisms. While the transmission of resistance from Enterococcus species to 
organisms such as S. aureus had been previously documented both in vitro and in vivo, 
it had never been reported to occur outside of a laboratory until very recently. In July, 
and again in October of 2002, the CDC reported isolates of S. aureus that were resistant 
to vancomycin. The first case involved a dialysis patient, who was documented to have 
both VRE and MRSA infections prior to development of vancomycin-resistant 
Staphylococcus aureus (VRSA) (33). This patient had also received several courses of 
vancomycin therapy. Fewer details were revealed concerning the second patient, but it 
is assumed that VRSA developed after conjugation between MRSA and VRE, as this 
isolate (like the previous specimen) was documented to possess the VanA phenotype 
(34). 
If the transmission of vancomycin resistance from Enterococcus species to other 
organisms were common, development of VRSA would likely have occurred much 
sooner after the appearance of VRE. Furthermore, one would expect that E. faecalis 
would quickly become the predominant species of VRE (as it is in VSE) if transmission 
of resistance through conjugation happened frequently. The fact that E. faecium 
comprises a high percentage of VRE isolates, but only a fraction of VSE isolates 
suggests that such transfer probably remains fairly rare. However, even if conjugation 
leading to the spread of resistance is rare, the transmission of vancomycin resistance is 
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no longer just a laboratory phenomenon, and must be considered in any 
recommendations concerning control of VRE. The development of vancomycin- 
resistance in a pathogenic organism such as S. aureus, which can be deadly even in 
immunocompetent hosts, eliminates the main therapeutic option for MRSA infections. 
Leaving only second-line therapy for such infections would surely lead to increased 
mortality due to such infections. For this reason alone, we should continue efforts to 
contain VRE, in spite of its low level of virulence. Such efforts can be focused on limiting 
risk factors for transmission of VRE that have been established in other studies and 
confirmed in this population, and also on general measures that serve to prevent 
transmission of all resistant microbes. 
Antibiotics 
This study confirmed that exposure to certain antibiotics is a risk factor for 
infection with VRE. In particular, administration of cephalosporins, especially those of 
the third generation, clearly leads to greater risk of VRE infection. It has long been 
known that enterococci are intrinsically resistant to cephalosporins, and it is believed that 
eliminating the microbial competition by other organisms allows for the proliferation of 
enterococci. Furthermore, this study confirmed parenteral vancomycin as a risk factor 
for the development of VRE. As mentioned previously, vancomycin and other 
glycopeptides are key to the induction of VanA resistance genes, thus selecting for the 
growth of enterococci possessing the genes for resistance. 
We also found that exposure to antibiotics with activity against anaerobes 
(metronidazole and clindamycin) was associated more strongly with VRE than VSE 
infection. This association received comment in previous studies (19, 24). The 
relationship we observed between exposure to fluoroquinolones and development of 
VRE was also noted in a previous study (13). Enterococci are known not only to 
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develop, but also to possess innate resistance to fluoroquinolones, so this association is 
not surprising. Furthermore, E. faecium has higher minimum inhibitory concentrations 
for fluoroquinolones than E. faecalis (MIC90 > 100 pg/mL for the former and M1C90 = 3.12 
pg/mL for the latter in one study) (35). 
These associations notwithstanding, a direct link between antibiotic exposure 
and development of VRE infections has not been proven. Administration of antibiotics to 
which enterococci are resistant could plausibly lead to overgrowth of enterococci on the 
skin or in bowel. Examination of skin and intestinal carriage of enterococci in patients 
with VRE bacteremia showed that 86% of these patients had VRE on their skin, and 
100% had positive rectal cultures indicating intestinal carriage (36). VRE carriage on the 
skin likely increases the likelihood that an IV catheter would provide a portal of entry into 
the bloodstream for VRE. We did not collect data on IV catheter use in our cohort of 
patients, but most of them (a significant proportion of whom were in the ICU) likely had 
some type of IV catheter. Previous studies have documented an association between 
central venous catheters and VRE bacteremia (19, 24). 
Another possible mechanism of progression from bacterial overgrowth to 
bacteremia could be through passage across the intestinal epithelium. Mice fed an oral 
inoculum of E. faecaiis and exposed to antibiotics without activity against enterococci 
were shown to develop disseminated infection with E. faecalis, including infection of the 
mesenteric lymph nodes, liver, and spleen (37). If the findings in mice can be 
extrapolated to humans, enterococci may be capable of translocating across an intact 
intestinal mucosa, using the portal venous system as a point of entry into the 
bloodstream. In addition, in a study of women undergoing gynecological surgery for 
removal of tumors, 46% of lymph nodes cultured yielded Enterococcus species, 
demonstrating the potential for translocation across the vaginal epithelium (38). 
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Evidence for enterococcal translocation across intact epithelium raises the 
possibility that this occurs commonly in humans, but a competent reticuloendothelial 
system is capable of eliminating the transient bacteremia. Perhaps administration of 
antibiotics leading to enterococcal overgrowth significantly increases the number of 
occurrences of bacterial translocation, overwhelming the reticuloendothelial system. 
Additionally, the reticuloendothelial system in debilitated hosts may be less efficient at 
clearing bacteria from the bloodstream. It is noteworthy that the administration of 
immunosuppressive agents, which would also limit the efficacy of the reticuloendothelial 
system, was found to be associated with VRE bacteremia in this study. Furthermore, 
many patients in this study were on chemotherapeutic regimens; in addition to 
suppressing the immune system, mucositis caused by such agents is likely to increase 
bacterial translocation, thus predisposing patients to bacteremia in multiple ways. 
Regardless of the mechanism linking antibiotic exposure to VRE bacteremia, the 
association between the two makes hospital formulary modifications a logical method for 
controlling VRE. Noskin et al. reported a significant decrease in the number of VRE 
isolates at Northwestern Memorial Hospital after restricting the use of third generation 
cephalosporins and encouraging the alternative use of ampicillin / sulbactam or 
piperacillin (39). Also, vancomycin has been used for routine surgical prophylaxis or 
treatment of infections without documented p-lactam resistance, but many hospitals are 
employing stricter controls on its use. Measures include pharmacist review of 
vancomycin orders, automatic queries when prescribing vancomycin to ensure the 
indication is valid, and automatic stopping of vancomycin orders if criteria for 
continuation of therapy are not met (8). Such formulary modifications have been shown 
to be effective in controlling outbreaks of VRE even after barrier precautions had failed 
to control the outbreak. One report describes limiting vancomycin, clindamycin, and 
cefotaxime use, as well as encouraging the substitution of penicillins and p-lactamase 
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inhibitors for third generation cephalosporins during an outbreak of VRE. Through these 
interventions, the hospital decreased the prevalence of fecal colonization with VRE from 
47% to 15 % (p < 0.001) (40). 
Additionally, out of concern for the development of infection with VRE, the 
Hospital Infection Control Practices Advisory Committee (HICPAC) recommends the use 
of metronidazole rather than vancomycin to treat C. difficile colitis. Although anti- 
anaerobic antibiotics have been associated with VRE infection (not a significant 
association in this study), the risk of vancomycin use leading to VRE infection is felt to 
be greater. 
Environmental factors 
While the effect did not reach statistical significance in our study, time spent in 
the ICU is another risk factor for the development of VRE infections. Severity of illness 
in the ICU often necessitates use of multiple antibiotics (including the aforementioned 
antibiotics that increase risk of infection with VRE), and the need for frequent patient 
contact in this setting undoubtedly contributes to the spread of resistant bacteria. 
Inadequate hand disinfection between patient encounters is likely to play a role in 
transmission of VRE, and routine patient-care items may also serve as vectors for 
resistant bacteria. For example, the handle of a thermometer probe in one hospital was 
documented to have led to new VRE colonization of several patients. Identification of 
the implicated vector was based on genetic analysis of both the patient isolates and the 
isolates found on the thermometer (41). To address these potential modes of spread, 
HICPAC recommends dedicating patient care items such as stethoscopes, IV poles and 
other minor items of equipment, to the rooms of VRE patients. 
In addition, alcohol-based hand cleansers may increase compliance with hand 
washing, thus helping to limit the spread of VRE. The institution of widely available 
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alcohol-based hand gels has improved hand hygiene compliance at Yale-New Haven 
Hospital since its introduction in August of 2001. After peaking in 2001, the number of 
patients with VRE bacteremia declined considerably in 2002, with only 9 such episodes 
documented. The addition of piperacillin / tazobactam to the formulary in September of 
2000 (as an alternative to third generation cephalosporins) was the only recent change 
in the formulary, and the number of episodes of VRE bacteremia peaked the following 
year. Thus, the introduction of alcohol-based hand gels in 2001 probably played a 
significant role in the marked decrease in episodes of VRE bacteremia in 2002. 
While it did not reach statistical significance in this study, dialysis was associated 
with VRE bacteremia (OR 1.92, 95% Cl 0.81 -4.54). An association between VRE and 
end-stage renal disease has been made previously (3, 13, 20). Vancomycin is 
frequently used to treat line infections caused by Staphylococcus species in dialysis 
patients. It has been suggested that renal-dosing of antibiotics (as is required for 
vancomycin and gentamicin - two anti-enterococcal agents) may lead to more frequent 
sub-therapeutic serum levels than traditional dosing (3). Whether this contributes to 
more frequent development of VRE in patients with end-stage renal disease is uncertain. 
Other factors associated with dialysis that could be associated with VRE infection could 
involve regular exposure to health-care equipment that is used by many different 
chronically ill patients. Enterococci, both those resistant to vancomycin and sensitive 
isolates, have been shown to persist on cotton, polyester, and plastic surfaces for more 
than 90 days (42). This mode of transmission among dialysis patients has not been 
documented, but the ability of enterococci to survive on the plastic and polyester - the 
same material found in dialysis machines or the furniture (beds, recliners, privacy 
curtains) found at dialysis centers - may be significant. Such regular exposure (a 
minimum of 3 times every week) to a potentially contaminated environment might 
increase VRE colonization if the environment is not adequately cleaned after each 
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patient encounter. Careful disinfection of all equipment, as well as dedicated equipment 
for patients who are colonized or infected with VRE could be used to limit transmission 
of VRE among dialysis patients. 
Limitations 
There are limitations to the current study. First, while this study was performed 
at a major university medical center, encompassing patients from a ten-year period, it is 
possible that the study population (including only 45 patients with clinically significant VS 
E. faecium bacteremia) was not large enough to detect a difference in outcome between 
VRE and VSE bacteremia. In fact, for this difference in mortality of 11.9% to be 
statistically significant with a power of 80%, we would have needed a total of 550 cases 
and controls. This is a direct consequence of our choice to include only E. faecium 
bacteremia. During the study period, there were an additional 8 patients with VRE 
bacteremia secondary to E. faecalis, and 685 patients with at least one positive blood 
culture for vancomycin-sensitive E. faecalis. However, in analyzing all blood cultures 
positive for Enterococcus species, 95% of the bacteremias in the VRE group were 
caused by E. faecium, while 85% of the VSE bacteremias were caused by E. faecalis. 
As inter-species differences would also affect outcome (confounding the effect of 
vancomycin-resistance on mortality), we concluded it was better to include only E. 
faecium in the test of our hypothesis. It is possible that only a multi-center study (or one 
at a hospital with a much higher prevalence of VRE) would generate sufficient data to 
detect a true difference in outcome between VR and VS E. faecium bacteremia, if such a 
difference exists. 
A second limitation to the current study may be in the use of a non-standardized 
measure of severity of illness. The Korvick scale was first used as a measure of degree 
of illness in patients with P. aeruginosa bacteremia, and was shown to be predictive of 
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outcome (25). It has since been used in studies of bacteremia caused by Enterobacter 
species (26) as weil as studies of enterococcal bacteremia (12, 15, 16, 24). While 
assessed parameters include mental status, temperature, blood pressure, and the need 
for mechanical ventilation, the scale does not encompass other measures of severity of 
disease, including co-morbid conditions (such as diabetes, coronary artery disease, 
oncologic diagnoses, HIV, etc.), laboratory values, and others. Our study attempted to 
account for co-morbid conditions by considering the need for dialysis, HIV status, 
requirement for surgery, and a history of organ transplant or cancer as part of the 
matching process. Since there was no observable difference between outcome of 
patients with VRE and VSE bacteremia after matching cases with controls, it is unlikely 
that failure to properly account for severity of illness affected our results. 
Another limitation of our study may lie in our definition of clinically significant 
bacteremia, requiring a minimum of two positive blood cultures or one positive blood 
culture with another documented site of infection. While our aim was to include only 
those with true bacteremia in the study, surely we inadvertently excluded patients with 
real bacteremia that did not conform to our definition. VRE bacteremia was more likely 
to be considered clinically significant than VSE bacteremia (OR 1.66, 95% Cl 1.02 - 
2.71). While this may simply be consistent with our finding that VRE is more likely to 
cause persistent bacteremia (and thus more likely to satisfy our definition of clinical 
significance), it might also suggest that we excluded more real VSE bacteremias than 
VRE bacteremias. One possible way that this could occur is through rapid treatment of 
VSE bacteremia. As susceptibility results often take a few days to return from the 
laboratory (but a Gram stain can quickly reveal the presence of gram positive 
bacteremia), vancomycin is a common empiric treatment for gram-positive bacteremia. 
Administration of vancomycin might prevent follow-up cultures from being positive in the 
case of VSE bacteremia (and preventing an episode from meeting our criteria of clinical 
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significance), but not if the organism is VRE. Another possible explanation for the higher 
percentage of clinically significant VRE bacteremia might be that clinicians were more 
comfortable in dismissing VSE as a skin contaminant, and forgoing follow-up cultures if 
only one set was positive. However, even if these mechanisms affected our study 
population, it is our feeling that a single blood culture in a colonized patient may reflect 
contamination. True infection is may be difficult to ascertain retrospectively. 
Furthermore, the alternative of including all patients with a single positive culture (or 
those with positive rectal cultures and a single positive blood culture) could create bias 
by adding more patients with pseudo-bacteremia than actual bacteremia. 
Finally, the limited numbers of patients in the study precluded a thorough multi¬ 
variate analysis of risk factors for VRE infection. For example, using univariate analysis, 
we found associations between different antibiotics and risk for VRE infection. However, 
many patients were on multiple antibiotics, and risk associated with vancomycin use 
could also be attributed to cephalosporins if the same patient were receiving multiple 
antibiotics. The consequence in such situations where patients received multiple 
antibiotics is an overstatement of the risk associated with each individual antibiotic. 
Similarly, while length of stay prior to development of bacteremia was associated with 
VRE infection, the increased likelihood of exposure to antibiotics during longer hospital 
stays could confound this association. 
Conclusion 
Vancomycin-resistance alone is not associated with increased mortality in 
patients with enterococcal bacteremia. However, this does not in itself obviate the 
importance of VRE. It has recently been demonstrated in two cases in the United States 
that vancomycin resistance can be transmitted from VRE to S. aureus, a much more 
serious pathogen. The potential for spread of resistance demands that we continue 
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efforts to control proliferation of VRE. Hospital formularies can be monitored more 
closely to ensure judicious use of cephalosporins and vancomycin, both of which 
contribute to the development of VRE. In addition, efforts to prevent transmission of 
VRE to dialysis, transplant, and ICU patients are indicated, as these patients are clearly 
at elevated risk for acquiring VRE. 
Furthermore, while the difference in pathogenicity between the enterococcal 
species has been observed before, it remains uncharacterized and under-recognized. 
The exact mechanism of these differences merits further investigation. Clearly, such 
inter-species differences in pathogenicity demand consideration in any future studies 




1. U.S. Congress, Office of Technology Assessment, Impacts of Antibiotic-Resistant Bacteria, 
OTA-H-629 (Washington, DC: U.S. Government Printing Office, September 1995). 
2. Cetinkaya, Y, Falk, P, and Mayhall, CG. 2000. Vancomycin-Resistant Enterococci. Clinical 
Microbiology Reviews, 13: 686-707. 
3. Uttley, A.H., Collins, C.H., Naidoo, J., and George, R.C. 1988. Vancomycin-Resistant 
Enterococci (letter). Lancet; 1: 57-58. 
4. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to 
vancomycin - United States, 1989-1993. MMWR: Morb Mortal Wkly Rep.', 42: 597-599. 
5. Hayden, M.K. 2000. Insights into the Epidemiology and Control of Infection with Vancomycin- 
Resistant Enterococci. Clinical Infectious Diseases; 31: 1058-65. 
6. Smith, T.L, Pearson, M.L., Wilcox, K.R., Cruz, C., Lancaster, M.V. et al. 1999. Emergence of 
Vancomycin Resistance in Staphylococcus aureus. New England Journal of Medicine', 
340(7): 493-501. 
7. Mackowiak, P.A. 1989. The Enterococci: Evidence of Species-Specific Clinical and 
Microbiologic Heterogeneity. The American Journal of the Medical Sciences', 297(4): 
238-243. 
8. Murray, B.E. 2000. Drug Therapy: Vancomycin-Resistant Enterococcal Infections. New 
England Journal of Medicine, 342: 710-721. 
9. Noble, W.C., Virani, Zarina, and Cree, R.G. 1992. Co-transfer of vancomycin and other 
resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. 
FEMS Microbiology Letters 72(2): 195-198. 
10. Fridkin, S.K., Edwards, J.R., Courval, J.M., Hill, H., Tenover, F.C. et al. 2001. The Effect of 
Vancomycin and Third-Generation Cephalosporins on Prevalence of Vancomycin- 
Resistant Enterococci in 126 U.S. Adult Intensive Care Units. Annals of Internal 
Medicine, 135(3): 175-183. 
11. Bhavnani, S.M., Drake J.A., Forrest, A., Deinhart, J.A., Jones, R.N. et al. 2000. A 
nationwide, multicenter, case-control study comparing risk factors, treatment, and 
outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagnostic 
Microbiology and Infectious Disease, 26: 145-158. 
12. Noskin, G.A., Peterson, L.R., and Warren, J.R. 1995. Enterococcus faecium and 
Enterococcus faecalis bacteremia: acquisition and outcome. Clinical Infectious Diseases; 
20: 296-301. 
13. Webb, Marcy, Riley, L.W., Roberts, R.B. 2001. Cost of Hospitalization for and Risk Factors 
Associated with Vancomycin-Resistant Enterococcus faecium Infection and Colonization. 
Clinical Infectious Diseases', 33: 445-452. 
14. Mainous, M.R., Lipsett, P.A., O’Brien, M., and the Johns Hopkins SICU Study Group. 1997. 
Enterococcal Bacteremia in the Surgical Intensive Care Unit: Does Vancomycin 
Resistance Affect Mortality? Archives of Surgery, 132: 76-81. 

41 
15. Stosor, V., Peterson, L.R., Postelnick, M., and Noskin, G.A. 1998. Enterococcus faecium 
Bacteremia: Does Vancomycin Resistance Make a Difference? Archives of Internal 
Medicine, 158: 522-527. 
16. Lautenbach, E., Bilker, W.B., and Brennan, P.J. 1999. Enterococcal Bacteremia: Risk 
Factors for Vancomycin Resistance and Predictors of Mortality. Infection Control and 
Hospital Epidemiology 1999; 20: 318-323. 
17. Lodise, T.P., McKinnon, P.S., Tam, V.H., and Rybak, M.J. 2002. Clinical Outcomes for 
Patients with Bacteremia Caused by Vancomycin-Resistant Enterococcus in a Level 1 
Trauma Center. Clinical Infectious Diseases; 34: 922-930. 
18. Linden, P.K., Pasculle, A.W., Manez, R., Kramer, D.J., Fung, J.J. et al. 1996. Differences in 
Outcomes for Patients with Bacteremia Due to Vancomycin-Resistant Enterococcus 
faecium or Vancomycin-Susceptible E. faecium. Clinical Infectious Diseases, 22: 663- 
670. 
19. Lucas, G.M., Lechtzin, N, Puryear, D.W., Yau, L.L., Flexner, C.W. et al. 1998. Vancomycin- 
Resistant and Vancomycin-Susceptible Enterococcal Bacteremia: Comparison of Clinical 
Features and Outcomes. Clinical Infectious Diseases, 26: 1127-1133. 
20. Tornieporth, N.G., Roberts, R.B., John, J., Hafner, A., and Riley, L.W. 1996. Risk Factors 
Associated with Vancomycin-Resistant Enterococcus faecium Infection or Colonization in 
145 Matched Case Patients and Control Patients. Clinical Infectious Diseases', 23: 767- 
772. 
21. Montecalvo, M.A., Shay, D.K., Patel, P., Tacsa, L., Maloney, S.A. et al. 1996. Bloodstream 
Infections With Vancomycin-Resistant Enterococci. Archives of Internal Medicine, 
156(13): 1458-1462. 
22. Traynor, P, Sahm, D, Mundy, L.M. 1997. Mortality Risk from Enterococcal Bacteremia 
Related to Species Rather than Vancomycin Resistance. Infection Control and Hospital 
Epidemiology 1997: 24: P32. (Abstr.) 
23. Edmond, M.B., Ober, J.F., Dawson, J.D., Weinbaum, D.L., and Wenzel, R.P. 1996. 
Vancomycin-Resistant Enterococcal Bacteremia: Natural History and Attributable 
Mortality. Clinical Infectious Diseases, 23: 1234-1239. 
24. Garbutt, J.M., Ventrapragada, M., Littenberg, B., and Mundy, L.M. 2000. Association 
between Resistance to Vancomycin and Death in Cases of Enterococcus faecium 
Bacteremia. Clinical Infectious Diseases, 30: 466-472. 
25. Korvick, J.A., Marsh, J.W., Starzl, T.E., and Yu, V.L. 1991. Pseudomonas aeruginosa 
bacteremia in patients undergoing liver transplantation: An emerging problem. Surgery, 
109(1): 62-68. 
26. Chow, J.W., Fine, M.J., Shlaes, D.M., Quinn, J.P., Hooper, D.C. et al. 1991. Enterobacter 
Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during Therapy. 
Annals of Internal Medicine, 115: 585-590. 
27. Pittet, D., Tarara, D., Wenzel, R.P. 1994. Nosocomial Bloodstream Infection in Critically III 
Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. Journal of the 
American Medical Association, 271: 1598-1601. 

42 
28. Wey, S.B., Mori, M., Pfaller, M.A., Woolson, R.F., Wenzel, R.P. 1988. Hospital-acquired 
Candidemia: the Attributable Mortality and Excess Length of Stay. Archives of Internal 
Medicine, 148: 2642-2645. 
29. Gullberg, R.M., Homann, S.R., and Phair, J.P. 1989. Enterococcal Bacteremia: Analysis of 
75 Episodes. Reviews of Infectious Diseases', 11(1): 74-85. 
30. Hoge, C.W., Adams, J., Buchanan, B., and Sears, S.D. 1991. Enterococcal Bacteremia: To 
Treat or Not to Treat, a Reappraisal. Reviews of Infectious Diseases', 13: 600-605. 
31. Jett, B.D., Huycke, M.M., and Gilmore, M.S. 1994. Virulence of Enterococci. Clinical 
Microbiology Reviews', 7(4): 462-478. 
32. Arduino, R.C., Palaz-Jacques, K., Murray, B.E., and Rakita, R.M. 1994. Resistance of 
Enterococcus faecium to neutrophils-mediated phagocytosis. Infection & Immunity, 62: 
5587-5594. 
33. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus Resistant to 
Vancomycin - United States, 2002. MMWR: Morb Mortal Wkly Rep.\ 51: 565-567. 
34. Centers for Disease Control and Prevention. 2002. Public Health Dispatch: Vancomycin- 
Resistant Staphylococcus aureus - Pennsylvania 2002. MMWR: Morb Mortal Wkly Rep.\ 
51:902. 
35. McNeely, D.F., Eckert, S.J., Noel, G.J. 2000. Antimicrobial-resistant enterococcal isolates 
from fluoroquinolones-nai've children. Pediatric Infectious Disease Journal; 19(7) 675. 
(letter) 
36. Beezhold, D.W., Slaughter, S., Hayden, M.K., Matushek, M., Nathan, C., et al. 1997. Skin 
Colonization with Vancomycin-Resistant Enterococci Among Hospitalized Patients with 
Bacteremia. Clinical Infectious Diseases, 24: 704-706. 
37. Wells, C.L., Jechorek, R.P., and Erlandsen, S.L. 1990. Evidence for the translocation of 
Enterococcus faecalis across the mouse intestinal tract. Journal of Infectious Diseases', 
162: 82-90. 
38. Wells, C.L., Jechorek, R.P., Twiggs, L.B., and Brooker, D.C. 1990. Recovery of viable 
bacteria from pelvic lymph nodes of patients with gynecologic tumors. Journal of 
Infectious Diseases', 162: 1216-1218. 
39. Noskin, G.A., Postelnick, M., and Peterson, L.R. 1994. Control of enterococci by restriction 
of third generation cephalosporins. Clinical Infectious Diseases; 19: 597. 
40. Quale, J., Landman, D., Saurina, G., Atwood, E., DiTore, V. et al. 1996. Manipulation of a 
Hospital Antimicrobial Formulary to Control an Outbreak of Vancomycin-Resistant 
Enterococci. Clinical Infectious Diseases', 23: 1020-1025. 
41. Livornese, LL, Dias, S., Samel, C., Romanowski, B., Taylor, S., et al. 1992. Hospital- 
acquired infection with vancomycin-resistant Enterococcus faecium transmitted by 
electronic thermometers. Annals of Internal Medicine', 117: 112-6. 
42. Neely, A N. and Maley, M.P. 2000. Survival of Enterococci and Staphylococci on Hospital 





HARVEY CUSHING/JOHN HAY WHITNEY 
MEDICAL LIBRARY 
MANUSCRIPT THESES 
Unpublished theses submitted for the Master’s and Doctor’s 
degrees and deposited in the Medical Library are to be used only with 
due regard to the rights of the authors. Bibliographical references 
may be noted, but passages must not be copied without permission of 
the authors, and without proper credit being given in subsequent 
written or published work. 
This thesis by 
has been used by the following person, whose signatures attest their 
acceptance of the above restrictions. 
NAME AND ADDRESS DATE 
YALE MEDICAL LIBRARY 

